This is a study of Kamlanoflast in patients with ALS. Kamlanoflast is orally administered over 24 weeks. Its effects on inflammatory and functional parameters will be studied. Information on safety and tolerability will be collected.
Diagnosis of definite, probable, laboratory-supported probable, or possible ALS by revised El Escorial research criteria.
Ages 18 to 75 years.
Onset of weakness within three years of study enrollment.
Inability to follow the study protocol, based on the investigator's assessment.
Pregnant or nursing women.
Recently（within 28 days）received other experimental treatments.
Presence of any active infections or inflammatory diseases at the time of enrollment that may confound the assessment of levels of inflammatory markers.
Inflammasome Therapeutics
Lead sponsor